Rucaparib Dosage

Medically reviewed by Drugs.com. Last updated on Nov 2, 2020.

Usual Adult Dose for Prostate Cancer

600 mg orally 2 times a day until disease progression or unacceptable toxicity

Comments:
-Patients taking this drug to treat mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
-Select patients for the treatment of epithelial ovarian, fallopian tube, primary peritoneal cancer, or metastatic castration-resistant prostate cancer based on the presence of a deleterious BRCA mutation (germline and/or somatic); the test is available at http://www.fda.gov/CompanionDiagnostics.

Uses:
-For maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy
-For the treatment of deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who have been treated with 2 or more chemotherapies
-For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

Usual Adult Dose for Ovarian Cancer

600 mg orally 2 times a day until disease progression or unacceptable toxicity

Comments:
-Patients taking this drug to treat mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
-Select patients for the treatment of epithelial ovarian, fallopian tube, primary peritoneal cancer, or metastatic castration-resistant prostate cancer based on the presence of a deleterious BRCA mutation (germline and/or somatic); the test is available at http://www.fda.gov/CompanionDiagnostics.

Uses:
-For maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy
-For the treatment of deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who have been treated with 2 or more chemotherapies
-For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

Usual Adult Dose for Fallopian Tube Cancer

600 mg orally 2 times a day until disease progression or unacceptable toxicity

Comments:
-Patients taking this drug to treat mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
-Select patients for the treatment of epithelial ovarian, fallopian tube, primary peritoneal cancer, or metastatic castration-resistant prostate cancer based on the presence of a deleterious BRCA mutation (germline and/or somatic); the test is available at http://www.fda.gov/CompanionDiagnostics.

Uses:
-For maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy
-For the treatment of deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who have been treated with 2 or more chemotherapies
-For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

Usual Adult Dose for Peritoneal Cancer

600 mg orally 2 times a day until disease progression or unacceptable toxicity

Comments:
-Patients taking this drug to treat mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
-Select patients for the treatment of epithelial ovarian, fallopian tube, primary peritoneal cancer, or metastatic castration-resistant prostate cancer based on the presence of a deleterious BRCA mutation (germline and/or somatic); the test is available at http://www.fda.gov/CompanionDiagnostics.

Uses:
-For maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy
-For the treatment of deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who have been treated with 2 or more chemotherapies
-For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

Renal Dose Adjustments

Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended.
Severe renal impairment (CrCl less than 30 mL/min): Data not available

Liver Dose Adjustments

Mild hepatic impairment (total bilirubin equal to ULN or less AND AST greater than ULN, OR total bilirubin between 1 to 1.5 x ULN AND any AST): No adjustment recommended.
Moderate to severe hepatic impairment (total bilirubin greater than 1.5 x ULN): Data not available

Dose Adjustments

Consider therapy interruption or dose reduction for adverse reactions.

RECOMMENDED DOSE REDUCTIONS:
-First dose reduction: 500 mg orally 2 times a day
-Second dose reduction: 400 mg orally 2 times a day
-Third dose reduction: 300 mg orally 2 times a day

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug may be taken with or without food.
-Administer each dose about 12 hours apart.
-If a patient misses a dose, instruct them to take the next dose at its scheduled time.
-Vomited doses should not be replaced.

Storage requirements:
-Store at room temperature between 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit).

General:
-The prostate cancer indication for this drug is under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
-Overdosage: Symptoms are not established and there is no specific treatment; use general supportive measures and treat symptomatically.

Monitoring:
-Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment.
-Oncologic: CBC (baseline and monthly thereafter; weekly for prolonged hematological toxicities)

Patient advice:
-Advise females patients of the potential risk to a fetus and to use effective contraception while on treatment and for 6 months after the last dose.
-Advise lactating women not to breastfeed during treatment and for 2 weeks after the last dose.
-Advise male patients not to donate sperm during therapy and for 3 months after the last dose.
-This drug may make your skin more sun-sensitive; avoid spending time in sunlight during treatment.
-When outdoors in sunlight during therapy with this drug, use sunscreen and wear clothes and a hat to cover your skin to help protect against sunburn.

Frequently asked questions

• What type of cancer is Rubraca used to treat?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer